Peginterferon alfa-2a
Pharmaceutical drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Peginterferon alfa-2a?
Summarize this article for a 10 year old
Pegylated interferon alfa-2a, sold under the brand name Pegasys among others, is medication used to treat hepatitis C and hepatitis B.[2] For hepatitis C it is typically used together with ribavirin and cure rates are between 24 and 92%.[2][3] For hepatitis B it may be used alone.[4] It is given by injection under the skin.[2]
Clinical data | |
---|---|
Trade names | Pegasys, others |
AHFS/Drugs.com | Professional Drug Facts |
MedlinePlus | a605029 |
License data | |
Pregnancy category |
|
Routes of administration | Subcutaneous injection |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL | |
Chemical and physical data | |
Formula | C860H1353N227O255S9 |
Molar mass | 19241.16 g·mol−1 |
NY (what is this?) (verify) |
Side effects are common.[5] They may include headache, feeling tired, depression, trouble sleeping, hair loss, nausea, pain at the site of injection, and fever.[2] Severe side effects may include psychosis, autoimmune disorders, blood clots, or infections.[2] Use with ribavirin is not recommended during pregnancy.[2] Pegylated interferon alfa-2a is in the alpha interferon family of medications.[2] It is pegylated to protect the molecule from breakdown.[5]
Pegylated interferon alfa-2a was approved for medical use in the United States in 2002.[2] It is on the World Health Organization's List of Essential Medicines.[6]